Skip to main content
  • AACR Journals
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Radiation Oncology
      • Novel Combinations
      • Reviews
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Journals
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Molecular Cancer Therapeutics
Molecular Cancer Therapeutics
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Radiation Oncology
      • Novel Combinations
      • Reviews
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Therapeutic Discovery

Safety, Pharmacokinetics, and Activity of GRN1005, a Novel Conjugate of Angiopep-2, a Peptide Facilitating Brain Penetration, and Paclitaxel, in Patients with Advanced Solid Tumors

Razelle Kurzrock, Nash Gabrail, Chandtip Chandhasin, Stacy Moulder, Carrie Smith, Andrew Brenner, Kamalesh Sankhala, Alain Mita, Kelly Elian, Danielle Bouchard and John Sarantopoulos
Razelle Kurzrock
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nash Gabrail
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Chandtip Chandhasin
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Stacy Moulder
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Carrie Smith
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Andrew Brenner
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kamalesh Sankhala
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alain Mita
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kelly Elian
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Danielle Bouchard
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
John Sarantopoulos
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1158/1535-7163.MCT-11-0566 Published February 2012
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Online Impact

Statistics from Altmetric.com

ARTICLE USAGE

ARTICLE USAGE: December 2011 to January 2021

AbstractFull-text HTMLPDF
Total408440842854

Cited By

Article Information

Volume 11, Issue 2, pp. 308-316

DOI 
https://doi.org/10.1158/1535-7163.MCT-11-0566
PubMed 
22203732

Published By 
American Association for Cancer Research
Print ISSN 
1535-7163
Online ISSN 
1538-8514
History 
  • Received July 25, 2011
  • Revision received November 2, 2011
  • Accepted December 1, 2011
  • Published first December 27, 2011.

Article Versions

  • Previous version (December 27, 2011 - 07:29).
  • You are viewing the most recent version of this article.
Copyright & Usage 
©2011 American Association for Cancer Research.

Author Information

  1. Razelle Kurzrock1,
  2. Nash Gabrail4,
  3. Chandtip Chandhasin1,
  4. Stacy Moulder2,
  5. Carrie Smith4,
  6. Andrew Brenner3,
  7. Kamalesh Sankhala3,
  8. Alain Mita3,
  9. Kelly Elian5,
  10. Danielle Bouchard5, and
  11. John Sarantopoulos3
  1. Authors' Affiliations: Departments of 1Investigational Cancer Therapeutics (Phase I Program) and 2Breast Medical Oncology, MD Anderson Cancer Center, Houston, Texas; 3Institute for Drug Development, Cancer Therapy and Research Center at University of Texas Health Science Center San Antonio, San Antonio, Texas; 4Gabrail Cancer Center, Canton, Ohio; and 5Angiochem Inc., Montreal, Québec, Canada
  1. Corresponding Author:
    Razelle Kurzrock, Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Unit 455, 1515 Holcombe Boulevard, Houston, TX 77030. Phone: 713-794-1226; Fax: 713-794-3249; E-mail: rkurzroc{at}mdanderson.org
View Full Text
PreviousNext
Back to top
Molecular Cancer Therapeutics: 11 (2)
February 2012
Volume 11, Issue 2
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover

Sign up for alerts

View this article with LENS

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Molecular Cancer Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Safety, Pharmacokinetics, and Activity of GRN1005, a Novel Conjugate of Angiopep-2, a Peptide Facilitating Brain Penetration, and Paclitaxel, in Patients with Advanced Solid Tumors
(Your Name) has forwarded a page to you from Molecular Cancer Therapeutics
(Your Name) thought you would be interested in this article in Molecular Cancer Therapeutics.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Safety, Pharmacokinetics, and Activity of GRN1005, a Novel Conjugate of Angiopep-2, a Peptide Facilitating Brain Penetration, and Paclitaxel, in Patients with Advanced Solid Tumors
Razelle Kurzrock, Nash Gabrail, Chandtip Chandhasin, Stacy Moulder, Carrie Smith, Andrew Brenner, Kamalesh Sankhala, Alain Mita, Kelly Elian, Danielle Bouchard and John Sarantopoulos
Mol Cancer Ther February 1 2012 (11) (2) 308-316; DOI: 10.1158/1535-7163.MCT-11-0566

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Safety, Pharmacokinetics, and Activity of GRN1005, a Novel Conjugate of Angiopep-2, a Peptide Facilitating Brain Penetration, and Paclitaxel, in Patients with Advanced Solid Tumors
Razelle Kurzrock, Nash Gabrail, Chandtip Chandhasin, Stacy Moulder, Carrie Smith, Andrew Brenner, Kamalesh Sankhala, Alain Mita, Kelly Elian, Danielle Bouchard and John Sarantopoulos
Mol Cancer Ther February 1 2012 (11) (2) 308-316; DOI: 10.1158/1535-7163.MCT-11-0566
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Patients and Methods
    • Results
    • Discussion
    • Disclosure of Potential Conflicts of Interest
    • Grant Support
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • Sorafenib Targets VCP in Hepatocellular Cancer Cells
  • RSK2 as Therapeutic Target for Myeloma
  • Dll4-Fc Suppresses Liver Metastasis of SCLC Cells
Show more Therapeutic Discovery
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About MCT

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Molecular Cancer Therapeutics
eISSN: 1538-8514
ISSN: 1535-7163

Advertisement